Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) Receives $11.89 Consensus Price Target from Analysts

Shares of Perspective Therapeutics, Inc. (NYSEAMERICAN:CATX) have been assigned an average recommendation of “Buy” from the eleven ratings firms that are currently covering the stock, MarketBeat reports. One research analyst has rated the stock with a hold recommendation, six have given a buy recommendation and four have assigned a strong buy recommendation to the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $10.7778.

CATX has been the topic of several recent research reports. B. Riley lowered their target price on Perspective Therapeutics from $12.00 to $11.00 and set a “buy” rating on the stock in a report on Tuesday. Wedbush reiterated an “outperform” rating and set a $11.00 price objective on shares of Perspective Therapeutics in a research report on Tuesday, November 11th. BTIG Research assumed coverage on Perspective Therapeutics in a research note on Friday, October 10th. They set a “buy” rating and a $14.00 price objective on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Perspective Therapeutics in a research note on Friday, October 3rd. Finally, UBS Group reiterated a “buy” rating and set a $7.00 price target (down previously from $18.00) on shares of Perspective Therapeutics in a report on Friday.

Hedge Funds Weigh In On Perspective Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. Nuveen LLC purchased a new stake in shares of Perspective Therapeutics in the 1st quarter valued at approximately $2,647,000. Affinity Asset Advisors LLC increased its stake in Perspective Therapeutics by 71.1% during the first quarter. Affinity Asset Advisors LLC now owns 2,224,196 shares of the company’s stock worth $4,738,000 after acquiring an additional 924,196 shares during the last quarter. Bank of America Corp DE increased its stake in Perspective Therapeutics by 139.9% during the third quarter. Bank of America Corp DE now owns 785,823 shares of the company’s stock worth $2,695,000 after acquiring an additional 458,323 shares during the last quarter. JPMorgan Chase & Co. raised its position in Perspective Therapeutics by 118.4% in the second quarter. JPMorgan Chase & Co. now owns 748,067 shares of the company’s stock valued at $2,573,000 after purchasing an additional 405,612 shares during the period. Finally, Patient Square Capital LP acquired a new position in shares of Perspective Therapeutics in the 3rd quarter valued at $1,198,000. 54.66% of the stock is currently owned by institutional investors and hedge funds.

Perspective Therapeutics Stock Performance

Perspective Therapeutics stock opened at $2.09 on Friday. Perspective Therapeutics has a 52-week low of $1.60 and a 52-week high of $5.39. The company has a fifty day simple moving average of $3.12 and a 200-day simple moving average of $3.30. The company has a quick ratio of 15.09, a current ratio of 15.09 and a debt-to-equity ratio of 0.01.

Perspective Therapeutics (NYSEAMERICAN:CATX) last posted its quarterly earnings results on Monday, November 10th. The company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.02). The business had revenue of $0.21 million during the quarter, compared to analysts’ expectations of $0.21 million. Perspective Therapeutics had a negative return on equity of 33.37% and a negative net margin of 7,688.50%. As a group, sell-side analysts predict that Perspective Therapeutics will post -0.88 EPS for the current year.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.